丽 珠Ｂ：第一季度报告全文（英文版） .ppt

,Full text f the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.Full Text of the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.1 Important notice1.1 The Board of Directors(BOD),Board of Supervisors(BOS),directors,supervisors,and seniorexecutives hereby guarantee that the data in the present report contain no false representation,misleading statements and serious omissions,and shall be severally and jointly liable for theauthenticity,accuracy and completeness of the content.1.2 The first quarterly report has not been audited by any accountants firms.1.3 Mr.Zhu Baoguo,principal of the Company,Mr.An Ning,the principal in charge of accounting,andMs.Si Yanxia,the principal of the Accounting Department hereby declare:We guarantee theauthenticity and completeness of the Financial Report in this quarterly report.2 Brief introduction of the Company2.1 Financial highlightsUnit:RMB Yuan,End of this reportperiod,End of previousYear,Increase ordecrease(%),Total assets(RMB Yuan)Owners equity attributable to the shareholders oflisted company(RMB Yuan)Total share capital(share)Net assets per share attributable to theshareholders of listed company(RMB Yuan/share)Total operating income(RMB Yuan)Net profit attributable to the shareholders of listedcompany(RMB Yuan)Net cash flows from operating activities(RMBYuan)Net cash flows per share from operating activities(RMB Yuan/share)Basic profit per share(RMB Yuan/share)Diluted profit per share(RMB Yuan/share)Weighed average yield rate of net assets(%)Weighed average yield rate of net assets afterdeduction of non-recurring profit and loss(%),4,554,878,274.852,959,205,752.55295,721,852.0010.01End of this reportperiod892,862,698.79117,291,231.12133,979,956.380.450.400.404.04%3.78%,4,602,908,981.742,843,169,706.20295,721,852.009.61Same period inprevious year749,385,019.01125,815,417.35118,304,818.200.400.430.434.88%4.46%,-1.04%4.08%0.00%4.16%Increase ordecrease(%)19.15%-6.78%13.25%12.50%-6.98%-6.98%-0.84%-0.68%,Items of non-recurring profit and loss Applicable InapplicableUnit:RMB Yuan,1,Items of non-recurring profit and lossProfit and loss in disposal of non-circulation assetsGovernmental allowance accrued to the current profit and loss,except those that are closely related to the normal operationbusinesses of company,comply with the national policies,and are co,Amount from the yearbeginning to end of reportperiod-57,599.762,130,166.86,Remarks(ifapplicable),-,Type,Full text f the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.ntinuously granted based on the certain standard quota or certainquantityExcept the effective hedge business related to the normal operationbusiness of the company,the profit and loss in the changes of fair,values caused by the holding of tradable financial assets andtradable financial liabilities as well as the investment returns indisposal of tradable financial assets,tradable financial liabilities andsaleable financial assetsOther net non-operating income and payment except the aboveitemsEffect of the minority of shareholders equitiesEffect of income taxTotal,5,536,835.64419,862.60-34,326.19-371,105.137,623,834.02,2.2 Table about total quantity of all shareholders and shareholding particulars of top tenshareholders without trading restriction at the end of report periodUnit:share,Total quantity of shareholders at the end ofreport period,The shareholder quantity of the company amounted to 29,329(including8,212 B-share holders),Shares held by top ten tradable shareholders without trading restrictionQuantity of tradable shares without,Shareholder name(full name),trading restriction at the end of reportperiod,Joincare Pharmaceutical Group Industry Co.,LtdTiancheng Industry Co.,LtdFirst Shanghai Securities Co.,LtdGAOLING FUND,L.P.Agricultural Bank of China-Greatwall Anxin ReturnMixed Securities Investment FundAgricultural Bank of China Penghua power growthmixed securities investment fundsShenzhen Haibin Pharmaceutical Co.,LtdBank of Communications-Great Wall Jiufu CoreGrowth Stock-type Securities Investment Fund(LOF)China Construction Bank Gongyin Ruixin BonusStock-type Securities Investment FundChina Construction Bank-Greatwall ConsumptionValue-added Stock-type Securities Investment Fund,77,510,16750,660,05210,295,54710,258,1126,250,0206,200,0005,892,9434,829,2862,887,4352,878,296,RMB common shareDomestically-listedshares for overseasinvestorsDomestically-listedshares for overseasinvestorsDomestically-listedshares for overseasinvestorsRMB common shareRMB common shareRMB common shareRMB common shareRMB common shareRMB common share,3 Major events3.1 Great changes and reasons of main financial statement items and financial indexes of theCompany Applicable Inapplicable3.1.1 Major changes of items in balance sheet and reasons2,Full text f the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.,Item,Amount at theend of period(RMB Yuan),Amount at thebeginning ofperiod(RMBYuan),Increaseordecrease,Cause,During the report period,while purchasing from,Notes receivable,88,113,442.56,171,033,783.72,-48.48%,outside,the company has employed thepayment mode by endorsement of the,acceptance bills.,EngineeringunderconstructionDepositreceivableOther currentliabilities,398,970,230.6625,637,619.63200,000,000.00,148,841,628.1639,028,703.01400,000,000,.00,168.05%-34.31%-50.00%,The new factory of Livzon Pharmaceuticalfactory is constructed,and the technicalimprovement project of Limin Pharmaceuticalfactory has increased relevant expenses.During the report period,the deposit receivableis used for offsetting the accounts receivable.The first installment of short-term financingbonds in 2011 has become due.,3.1.2 Major change of items in Profit Statement and reasons,ItemOperating tax andsurtax,Amount in thisperiod(RMBYuan)11,757,363.91,Amount inprevious period(RMB Yuan)8,351,082.68,Changerate40.79%,CauseThe sales incomes have increased,andthe city construction tax and educationalsurtax have increased correspondingly.,The business investment has increased,Sales expense,320,103,016.74,174,436,383.41,83.51%,due to the sales business expansion and,reform of sales mode.,Financial expense,-4,885,220.34,-1,365,483.72,257.76%,During the report period,the interestsincomes have increased.,Returns from the,The fair prices of tradable financial assets,changes of fair,4,971,946.09,1,541,484.96,222.54%,have changed.,values,Investment returns,347,088.76,-693,022.78,150.08%,Part of tradable financial assets has beendisposed of.,The governmental allowances that are,Non-operating,2,612,890.25,11,690,162.11,-77.65%,accrued to current profit and loss have,income,decreased.,3.1.3 Major change of items in cash flow Statement and reasons,Item,Amount in thisperiod(RMBYuan),Amount inprevious period(RMB Yuan),Changerate,Cause,Cash received from sales,The incomes from purchase of,of goods or rendering ofservices,889,352,722.29,675,234,349.70,31.71%,prescription medicines have increaseddue to the influence of sales reform.,The value-added tax,city construction,Tax payments,129,595,034.42,98,584,528.88,31.46%,tax and educational surtax haveincreased due to the expansion of sales,scale of company.The expense payment ratio has,Cash paid to otheroperating activities,340,933,100.04,187,318,033.83,82.01%,improved and the business expense ofsales has increased due to the sales,reform.,Cash receivedinvestment returns,from,1,116,870.13,19,433.44,5647.16%,Part of tradable financial assets hasbeen disposed of.,3,-,-,Full text f the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.,Cash paid to acquire andconstruct fixed assets,intangible assets andother long-term assets,213,873,211.70,53,807,149.52,297.48%,During the report period,the companyhas paid the expenses for Ningxia LivzonIndustrial Park project and technicalimprovement project of LiminPharmaceutical Factory.,During the same period of previous year,Cashinvestors,received,by,9,800,000.00,-100.00%,Dankang Company received theinvestments from Joincare,but thecompany has received no investments in,this period.During the same period of previous year,Cash from loans,24,405,000.00,59,215,460.00,-58.79%,the foreign-currency loans have becomedue and exchanged,but the company,has made no exchange in this period.During the report period,the company,Cash paid for distributionof dividends,profits andrepayment of interests,21,688,903.53,3,073,977.57,605.56%,has paid the interests for 2011 firstinstallment of short-period financingbonds and Livzon Reagents Co.,Ltd haspaid the bonus to the minority of,shareholders.During the same period of previous year,Cash payments related toother financing activities,800,000.00,-100.00%,the company paid the issuing expensesfor first installment of short-periodfinancing bonds,but the company has,made no payment in this period.3.2 Analysis and particulars of major events,their effects and resolutions3.2.1 Non-standard opinions Applicable Inapplicable3.2.2 Particulars about the Company providing the capitals to the controlling shareholders andtheir associated parties or providing the external guaranty by violating the relevant regulationsand procedures Applicable Inapplicable3.2.3 Particulars about the company signing and performing the major routine operationcontracts.Applicable Inapplicable3.2.4 Others Applicable Inapplicable3.3 Performance of commitments by the Company,shareholders and actual controllersApplicable Inapplicable(I)Commitments of the Company1.In 2002,This Company signed the patent license agreement with Korea Yiyang Medicine Company.This agreement approves our companys exclusive and irrevocable right to use the patent PPI(proton pump inhibitor)compound and Yiyangpatent in China including Hong Kong and Macao for the purpose of production,processing and distribution.The transfer fee will be USD 2.50 million,and by December 31,2008,the company has fully paid it.The company agrees to give Yiyan4,1,2,3,4,5,6,Full text f the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.g the commission of 10%of sales amount during the first three years when this product begins to be sold,8%of sales amount during the next five years,and 6%of sales amount from the remaining time to July 22,2014(the expiry date of agreement).Since 2009,the company has started the sales and paid the commissions in accordance with the agreement.2.In 2005,the company signed the approval and supply agreement with Korea LG life science Ltd.(hereinafter referredto as LG Company),and it grants Gemifloxacin Mesylate with the relevant certificates about intellectual properties andspecifies that the permission fees of the methanesulfonic acid spasmolytic and pellet will be USD1,000,000 respectively(they have been fully paid by December 31,2006).This agreement specifies as follows:Within the first five years from the validity date of the agreement,the companys net sales volume of above final pelletproducts will amount to 1.5 million bags(3 pellets in each bag)and LG Company will refund USD 500,000 after thetaxation at one time within two months after the company has submitted the net sales volume certificate.At the same time,during the validity period of the agreement(by the end of 2015),the company should pay a royalty of 1.5%of net salesvolume after the taxation to LG Company during 30 days after each quarter.The company has begun the selling activitiesin 2008 and paid the royalties in accordance with the agreements.Within the first five years from the validity date of the agreement,the company will pay a royalty of 10%of net sales volume after the taxation about injection products to LG Company within 30 days after each quarter.The company will pay a royalty of 6%of net sales volume after the taxation about injection products to LG Company within 30 days after each quarterfrom the sixth business year to the expiry date of agreement(by the end of 2019).(II)Commitments of shareholders holding over 5%of total shares of the companyDuring the report period,the controlling shareholder Joincare made the following commitments while handling therestriction release of shares with trading restriction:1.When Joincare transfers its tradable shares of Livzon Group whosetrading restriction has been released,it will strictly comply with the relevant regulations of the Guiding Opinions on theListed Companies Transfer of Original Shares Released from Trading Restrictions(2008 No.15 announcement)issuedby China Securities Regulatory Commission.(2)Joincare plans to reduce its tradable shares of Livzon Group whosetrading restriction has been released through the competing price trading system in the stock exchange in the future andthe reduced quantity of shares amounts to over 5%within 6 months from the first reduction,then Joincare will disclose thereminder announcement about the selling affairs via Livzon Group in 2 trading days before the first reduction.During the report period,Joincare did not decrease the stocks issued by the company.3.4 Warning and relevant reasons for the forecast that the accumulative net profit from thebeginning of 2011 to the end of next report period may suffer from any loss or have any greatchanges over the same period of previous year Applicable Inapplicable3.5 Particulars about Other Major events3.5.1 Particulars about Securities investment Applicable InapplicableUnit:RMB Yuan,No.,SecuritiesTypeStockStock,SecuritiesCode0013500152,SecuritiesabbreviationKunlunEnergyShenzhenInternational,Initialinvestmentamount(RMB Yuan)6,514,464.439,350,227.22,Holdingquantity(share)1,500,00017,000,000,Book Valuesat the end ofperiod(RMBYuan)17,023,230.007,441,583.40,Percentage oftotal investmentin the securitiesat the end ofperiod(%)34.91%15.26%,Profit andloss duringthe reportperiod(RMBYuan)3,575,054.70413,441.70,China,Stock,00883,NationalOffshore Oil,2,656,235.91,560,000,7,245,086.69,14.86%,1,080,460.98,Corporation,StockStockStock,020070188000438,PhoenixIslandBailiCompanyRainbow gro,19,326,101.942,172,792.245,794,680.85,2,450,000428,0005,016,000,5,918,409.634,836,477.981,545,125.63,12.14%9.92%3.17%,139,029.91138,786.70-223,647.64,5,7,8,9,-,-,-,-,-,Full text f the 2012 First Quarterly Report of Livzon Pharmaceutical Group Inc.up,Stock,01688,Alibaba,862,206.15,78,000,834,624.65,1.71%,326,910.78,China,Stock,00390,RailwayEngineering,1,486,073.30,314,000,633,799.17,1.30%,15,273.02,Group Co.China,Stock,00186,RailwayConstruction,998,783.53,114,000,446,349.09,0.92%,50,829.01,Corporation,10,Stock,00368,SinotransShipping,1,744,792.46,260,500,392,774.55,0.81%,-6,335.39,Other securities investment at theend of this period,828,090.23,2,441,462.31,5.01%,15,179.55,Profit and loss of sold Securitiesinvestment during the report periodTotal,-51,734,448.26,-,-48,758,923.10,-,100%,11,852.325,536,835.64,Explanation about securities investment:The above securities investments are the investments in the H-share market.The amounts of H-share investment have been converted to RMB at the exchange rate at the end of report period.3.5